AGENUS INC.

Agenus Inc. executives and directors misled the public about clinical trials for their cancer treatment, breaching fiduciary duties, according to a shareholder derivative suit. The false statements involved a combination therapy for metastatic colorectal cancer, which Agenus promoted until the FDA advised against submitting trial results.

Save time by focusing on key insights.

Pomerantz LLP announces a class action lawsuit against Agenus Inc. and certain officers, alleging false and misleading statements regarding the effectiveness of botensilimab and balstilimab combination therapy. The lawsuit seeks damages for shareholders who purchased Agenus securities between January 23, 2023, and July 17, 2024. Shareholders have until November 5, 2024, to join the lawsuit.